Santhera Pharmaceuticals announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
阅读更多： Agamree (vamorolone) 是什么？Agamree 的用途是什么？
Supply and sales by GEN are expected to start in the first half of 2026, initially on a named patient basis, followed by commercial sales. Santhera has received a small upfront payment and, as per previous agreements, will receive an ongoing percentage of net sales.
Dario Eklund, Chief Executive Officer of Santhera, said: “As leaders in the Turkish specialty pharmaceuticals market, GEN were a natural choice for Santhera as we looked for a high-quality distribution partner. We look forward to working closely in the run up to launching in the country in 2026, to provide access to the many DMD patients lacking suitable treatment options.”
了解更多： 神奇类固醇 Vamorolone (Agamree) 可以为 DMD 提供更安全的治疗
Abidin Gülmüş, Chairman/CEO of GEN, added: “The potential for AGAMREE is clear, and we are determined to ensure this DMD therapy reaches patients in Türkiye without delay. We understand the rare disease market deeply, use our longtime experience on neuromuscular diseases and look forward to partnering with Santhera in the months and years ahead.”
Turkish: GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN)
